DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “In
Vitro Fertilisation (IVF) Market – Forecasts from 2017 to 2022”
report to their offering.
In 2022, the market for In Vitro Fertilization (IVF) is expected to
reach US$13.498 billion, increasing from US$8.418 billion in 2017,
growing at a CAGR of 9.90%.
In vitro fertilization (IVF) is a procedure used to treat fertility
problems and support conception of a child by collecting mature eggs
from a healthy woman’s ovaries and fertilizing them in a laboratory.
Demand for IVF procedures has increased in recent years, owing to rising
awareness and social acceptability.
Factors driving growth in the market are an increasing number of cases
of infertility owing to lifestyle changes involving unhealthy
nutritional habits, penetration of advanced procedures in developing
nations, and favorable government initiatives. Geographically, the
Asia-Pacific is expected to witness the highest growth owing to a rising
aging population in Japan, favorable childbearing policies in China and
rising awareness in countries like India, South Korea, and Thailand.
Key industry players profiled as part of this section are Vitrolife AB,
Irvine Scientific, Thermo Fisher Scientific and OvaScience Inc., among
By Donor Type:
- Fresh Donor
- Frozen Donor
- Hospitals and Clinics
- Research Laboratories
- Genea Biomedx
- Irvine Scientific
- Merck KGaA
- OvaScience Inc.
- Oxford Gene Technology
- Progyny Inc.
- Thermo Fisher Scientific
- Vitrolife AB
For more information about this report visit http://www.researchandmarkets.com/research/fpcvd3/in_vitro.
Research and Markets
Laura Wood, Senior Manager
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716